Home > Article > Erratum to: Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study
Headache Disorders
Read Time: < 1 min

Erratum to: Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study

Published Online: December 17th 2019 European Neurological Review, 2020;15(1):[online only]
Authors: Uwe Reuter
Quick Links:
Article
Article Information
Article:

In the originally published article there was an error in Table 1. The reduction in monthly migraine days over 12 weeks versus placebo with quarterly fremanezumab was incorrectly given as “-0.6”; this should read “-3.7”.

Article Information:

Further Resources

Related Content In Headache Disorders
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar